Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Theriva Biologics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +3 vs. Q2 2023
- Shares held
- 1.06M
- +55.3K (+5.5%) vs. Q2 2023
- Total value
- $572.8K
- −$434.9K (−43.2%) vs. Q2 2023
- New holders
- 4
- 4 more added
- Sold out
- 1
- 2 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 512,763 | $276.5K | 0.00% | −12,604−2.4% | Reduced |
| BlackRock Inc. | 190,169 | $102.6K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 141,168 | $76.2K | 0.00% | +24,867+21.4% | Added |
| Renaissance Technologies LLC | 54,210 | $29.0K | 0.00% | +15,500+40.0% | Added |
| State Street Corp | 48,691 | $26.3K | 0.00% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 28,528 | $15.4K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 26,599 | $14.3K | 0.00% | 00.0% | Unchanged |
| Jane Street Group, LLC | 17,334 | $9.35K | 0.00% | +17,334 | New |
| Two Sigma Securities, LLC | 15,968 | $8.61K | 0.00% | +15,968 | New |
| Charles Schwab Investment Management Inc | 13,566 | $7.32K | 0.00% | 00.0% | Unchanged |
| Fisher Asset Management, LLC | 12,569 | $6.78K | 0.00% | 00.0% | Unchanged |
| IFP Advisors, Inc | 382 | $206 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 145 | $78 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 124 | $67 | 0.00% | +15+13.8% | Added |
| FMR LLC | 100 | $54 | 0.00% | +100 | New |
| Advisor Group Holdings, Inc. | 89 | $47 | 0.00% | +42+89.4% | Added |
| Steward Partners Investment Advisory, LLC | 14 | $8 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 15 | $8 | 0.00% | +15 | New |
| Morgan Stanley | 10 | $5 | 0.00% | −2−16.7% | Reduced |
| Bank of America Corp | 6 | $3 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 7 | $0 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 0 | $0 | 0.00% | −5,933−100.0% | Sold out |